No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.
Can healthy immune cells from a patient be frozen and used in the future to make adoptive cell therapies in the event of a cancer diagnosis?
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
A considerable proportion of patients with Waldenström macroglobulinemia experience disease-related adverse events, such as hyperviscosity and neuropathy.
Pancreatic ductal adenocarcinoma is characterized by a tumor microenvironment that inhibits immune signaling.
Oncologists lacking long-term data now have more information on relapse rates and the role of obesity in treatment success.
Data could support regulatory, payer decision making.
This fact sheet explains the processes involved in drug development and FDA drug approval.
Patients are now able to get immunotherapies and targeted therapies at their local clinics, rather than having to travel to academic medical centers.
A retrospective review of data reveals frequency of recurrent immune-mediated diarrhea and colitis with resumption of ICI therapy after an initial adverse event.
